|
|
Volumn 50, Issue 14, 2014, Pages 2408-2416
|
|
A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery
|
|
Author keywords
Angiogenesis inhibitors; Angiopoietin 1; Angiopoietin 2; Combination drug therapy; Tie2 receptor
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
ANTINEOPLASTIC AGENT;
CARBOPLATIN;
HYBRID PROTEIN;
PACLITAXEL;
TRENANANIB;
ADULT;
AGED;
CLINICAL TRIAL;
COHORT ANALYSIS;
FEMALE;
HUMAN;
METABOLISM;
MIDDLE AGED;
MULTICENTER STUDY;
MULTIMODALITY CANCER THERAPY;
OVARIAN NEOPLASMS;
PHASE 1 CLINICAL TRIAL;
TREATMENT OUTCOME;
ADULT;
AGED;
ANGIOGENESIS INHIBITORS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARBOPLATIN;
COHORT STUDIES;
COMBINED MODALITY THERAPY;
FEMALE;
HUMANS;
MIDDLE AGED;
OVARIAN NEOPLASMS;
PACLITAXEL;
RECOMBINANT FUSION PROTEINS;
TREATMENT OUTCOME;
|
|
EID: 85027945168
PISSN: None
EISSN: 18790852
Source Type: Journal
DOI: 10.1016/j.ejca.2014.06.010 Document Type: Article |
|
Times cited : (21)
|
|
References (0)
|
